Adial Pharmaceuticals Inc. [NASDAQ: ADIL] gained 2.03% or 0.03 points to close at $1.51 with a heavy trading volume of 1922163 shares. The company report on August 6, 2020 that Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits.
CHARLOTTESVILLE, VA / ACCESSWIRE / August 6, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has entered into an agreement with Brik LLC (“Brik”), an independent sales and marketing firm, to act as a third-party agent to Adial for the sale and distribution of Rapid Result COVID-19 antibody test kits. As reported on June 8, 2020, Adial and BioLab Sciences, Inc. entered into a distribution agreement, whereby Adial has the exclusive rights to sell and distribute the Rapid Result COVID-19 antibody tests to designated channel partners and customers.
Gérard Brikkenaar Van Dijk, Principal and co-founder of Brik, commented, “We are delighted to partner with Adial to advance the sales, marketing and distribution of the Rapid Result COVID-19 antibody test kits. These FDA emergency use authorization (EUA) registered tests provide results within 10-minutes, with the ability to detect both lgG and lgM antibodies specific to SARS-CoV-2. Importantly, these tests are able to detect IgG antibodies at a 98.6% accuracy and IgM antibodies at a 92.9% accuracy. We see significant market potential for this differentiated test kit, given the prolonged and devastating impact of COVID-19. We look forward to leveraging our global network of suppliers and end-users to help bring the product to market in a timely and cost-effective manner.”.
It opened the trading session at $1.47, the shares rose to $1.59 and dropped to $1.43, the range by which the price of stock traded the whole day. The daily chart for ADIL points out that the company has recorded -13.22% loss over the past six months. However, it is still -51.0% lower than its most recent low trading price.
If we look at the average trading volume of 983.42K shares, ADIL reached to a volume of 1922163 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Adial Pharmaceuticals Inc. [ADIL]:
Maxim Group have made an estimate for Adial Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 30, 2018. The new note on the price target was released on October 11, 2018, representing the official price target for Adial Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Adial Pharmaceuticals Inc. is set at 0.18 The Price to Book ratio for the last quarter was 1.94, with the Price to Cash per share for the same quarter was set at 0.61.
Trading performance analysis for ADIL stock
Adial Pharmaceuticals Inc. [ADIL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.36. With this latest performance, ADIL shares gained by 7.86% in over the last four-week period, additionally sinking by -13.22% over the last 6 months – not to mention a drop of -10.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADIL stock in for the last two-week period is set at 45.92, with the RSI for the last a single of trading hit 41.70, and the three-weeks RSI is set at 47.89 for Adial Pharmaceuticals Inc. [ADIL]. The present Moving Average for the last 50 days of trading for this stock 1.5153, while it was recorded at 1.5180 for the last single week of trading, and 1.6098 for the last 200 days.
Adial Pharmaceuticals Inc. [ADIL]: A deeper dive into fundamental analysis
Return on Total Capital for ADIL is now -142.38, given the latest momentum, and Return on Invested Capital for the company is -148.36. Return on Equity for this stock declined to -148.36, with Return on Assets sitting at -138.81.
Reflecting on the efficiency of the workforce at the company, Adial Pharmaceuticals Inc. [ADIL] managed to generate an average of -$2,147,857 per employee.Adial Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.90 and a Current Ratio set at 13.90.
Adial Pharmaceuticals Inc. [ADIL]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Adial Pharmaceuticals Inc. posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.18/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -50.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADIL.
An analysis of insider ownership at Adial Pharmaceuticals Inc. [ADIL]
There are presently around $1 million, or 10.00% of ADIL stock, in the hands of institutional investors. The top three institutional holders of ADIL stocks are: VANGUARD GROUP INC with ownership of 282,909, which is approximately 0% of the company’s market cap and around 6.20% of the total institutional ownership; BLACKROCK INC., holding 205,684 shares of the stock with an approximate value of $0.31 million in ADIL stocks shares; and BANK OF AMERICA CORP /DE/, currently with $0.23 million in ADIL stock with ownership of nearly New of the company’s market capitalization.
Positions in Adial Pharmaceuticals Inc. stocks held by institutional investors increased at the end of June and at the time of the June reporting period, where 3 institutional holders increased their position in Adial Pharmaceuticals Inc. [NASDAQ:ADIL] by around 198,178 shares. Additionally, 3 investors decreased positions by around 16,864 shares, while 7 investors held positions by with 598,212 shares. The mentioned changes placed institutional holdings at 813,254 shares, according to the latest SEC report filing. ADIL stock had 2 new institutional investments in for a total of 192,007 shares, while 2 institutional investors sold positions of 15,251 shares during the same period.